CBD shows promise in easing opioid cravings and anxiety

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals between 18 and 65 years old. * Current methadone maintenance in an opioid treatment program with a dose of =/\>40mg for at least 14 days prior to participation and prescribed take-home methadone medication. * Current opioid use disorder (OUD) or OUD in remission while on maintenance therapy with opioid agonist therapy (OAT), as determined by DSM-5 with the M.I.N.I. interview (Mini-International Neuropsychiatric Interview). * Urinary toxicology positive for methadone. Exclusion Criteria: * Non-English speaking. * Court mandate to treatment. * Participation in another pharmacotherapeutic trial in the past 3 months. * Poor physical health (as determined by medical screen) that would make study participation unsafe, or would prevent adherence to study procedures, including a history of cardiac disease, arrhythmias, head trauma, and seizures. * Psychiatric conditions under DSM-5 (examined with the MINI) that would make study participation unsafe or which would prevent adherence to study procedure; examples include: suicidal or homicidal ideation requiring immediate attention, or inadequately-treated mental health disorder (e.g. active psychosis or uncontrolled bipolar disorder). * History of impaired renal function or elevated liver enzymes \>2x the normal at prescreening. * QTc Frederica \>500ms. * Current pregnancy \[determined by positive urine test\] or breastfeeding. * Not using an appropriate method of contraception such as hormonal contraception (oral hormonal contraceptives, Depo-Provera, Nuva-Ring), intrauterine device (IUD), sterilization, or double barrier method (combination of any two barrier methods used simultaneously, i.e. condom, spermicide, diaphragm). * Medical or psychiatric contraindications for MRI (metal implants, stents, etc). * Medical or psychiatric contraindications for CBD administration (e.g., history of hypersensitivity to cannabinoids). * Current diagnosis of a moderate or severe substance use disorder (except for opioids and nicotine) in the past 3 months, based on DSM-5. * Acute drug intoxication as determined by clinician assessment. * Acute opioids withdrawal symptoms (observational and determined by the Clinical Opiate Withdrawal Scale (COWS). A Score of ≥#5 will be considered a positive result for withdrawal symptoms and/or by clinical judgment. * Breathalyzer/Alcohol salivary/urine strips positive for alcohol.